Digestive Disease Interventions 2020; 04(02): 206-213
DOI: 10.1055/s-0040-1712120
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genomics and Interventional Oncology in Metastatic Liver Cancer

Meaghan Dendy Case
1   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
,
Ryan Slovak
1   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
2   University of Connecticut School of Medicine, Farmington, Connecticut
,
Hyun S. Kim
1   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
3   Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
4   Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
› Institutsangaben

Funding H.S.K. is supported by the United States Department of Defense (CA160741). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Weitere Informationen

Publikationsverlauf

02. Januar 2020

16. März 2020

Publikationsdatum:
25. Mai 2020 (online)

Preview

Abstract

This review aims to investigate the current literature on genetic and genomic biomarkers of locoregional interventions on metastatic liver metastases. A brief overview on the most common cancers that metastasize to the liver and the role locoregional therapies, such as ablation, chemoembolization, and radioembolization, play in their treatment will be presented. Review of the literature on the genetic, metabolic, and other molecular biomarkers and how they relate to posttreatment survival and outcomes will be discussed. Evaluation of how the existing data can better inform decisions regarding locoregional treatments in those patients with metastatic lesions of the liver will be completed. Personalized treatment paradigms in different types of metastatic cancer present significant opportunities for improved overall clinical outcomes. Optimizing patient selection for localized treatments is vital to improving outcomes and determining which biomarkers correlate with improved efficacy presents many avenues for future research.